Your skin is a living wall, held together by a precisely timed demolition system. As dead cells reach the outermost layer, proteases called kallikreins¹¹ kallikreins
serine protease enzymes (KLK5, KLK7) that cleave the protein bridges holding corneocytes together, driving the orderly shedding of dead skin cells dissolve the protein links between them so they can shed naturally. The braking system for this process is a multi-domain protease inhibitor called LEKTI²² LEKTI
Lympho-Epithelial Kazal-Type Inhibitor, the protein encoded by SPINK5; contains 15 serine protease inhibitory domains and is expressed in skin, thymus, and mucous membranes, encoded by the SPINK5 gene. When LEKTI malfunctions, kallikrein proteases run unchecked — and the result is a compromised skin barrier, inflammation, and atopic disease.

The rs2303067 variant (c.1258A>G in coding notation; note that the GRCh38 plus-strand reference allele is A, which encodes Lys420, the risk form) introduces a single amino acid change in domain 6 of LEKTI: lysine at position 420 is replaced by glutamic acid (p.Lys420Glu). The G allele (Glu420) is actually the slightly more common and protective allele globally (about 52% by gnomAD v4); the A allele (Lys420) is the risk variant carried by approximately 48% of the global population. Carrying one or two copies of the A allele means your LEKTI protein is processed abnormally — with real consequences for skin barrier integrity and atopic disease risk.

The Mechanism

The Lys420 substitution (A allele) has been characterised at the molecular level by Fortugno et al. in a landmark 2012 functional study. The Lys residue at position 420 sits in the linker region between LEKTI inhibitory domains D6 and D7 — a region that is a substrate for furin, a cellular proprotein convertase³³ proprotein convertase
enzyme that cleaves precursor proteins at specific dibasic amino acid sequences, processing them into functional mature forms.

Normally, the LEKTI precursor is processed by furin into a series of overlapping inhibitory fragments. One of the most potent is the D6–D9 fragment, which has the strongest inhibitory activity against KLK5-mediated desmoglein-1 (DSG1) degradation⁴⁴ KLK5-mediated desmoglein-1 (DSG1) degradation
desmoglein-1 is a key structural protein of corneodesmosomes — the rivets holding skin cells together; when KLK5 cleaves it, desquamation proceeds; LEKTI fragment D6–D9 prevents this cleavage. The Lys420 substitution accelerates furin-mediated cleavage within the D6–D7 linker, destroying the D6–D9 fragment before it can form. The result is a functional LEKTI deficit: KLK5, KLK7, and elastase-2 are insufficiently inhibited, desmoglein-1 is over-cleaved, profilaggrin breakdown accelerates, and the skin barrier weakens. Compounding this, epidermis from Lys420/Lys420 donors shows elevated expression of TSLP⁵⁵ TSLP
thymic stromal lymphopoietin, a cytokine released by barrier- disrupted keratinocytes that drives Th2 immune skewing and atopic sensitisation, directly linking the structural barrier defect to atopic inflammation.

The Evidence

The clearest genetic signal for rs2303067 comes from disease-subtype analysis. A Slovenian case- control study by Dežman et al.⁶⁶ Dežman et al.
SPINK5 is associated with early-onset and CHI3L1 with late-onset atopic dermatitis. Int J Immunogenet, 2017 enrolled 241 atopic dermatitis patients and 164 healthy controls and found that rs2303067 was significantly associated specifically with early-onset AD (onset ≤8 years: OR=2.57, p=0.003). It was also associated with disease severity markers: hospitalization requirement (OR=2.76, p=0.006), disease duration ≥10 years (OR=2.32, p=0.008), and involvement of multiple body parts (OR=2.01, p=0.015).

The clinical significance is underscored by a 2023 case report from Moltrasio et al.⁷⁷ Moltrasio et al.
Netherton Syndrome Caused by Heterozygous Frameshift Mutation Combined with Homozygous c.1258A>G Polymorphism in SPINK5 Gene. Genes (Basel), 2023 describing a patient who developed Netherton syndrome with the combination of a heterozygous frameshift mutation AND homozygous rs2303067. The authors note that homozygous Lys420/Lys420 alone carries approximately 1.8× the population risk for atopic dermatitis, and when combined with a loss-of-function SPINK5 allele, produces haploinsufficiency sufficient for a full Netherton phenotype.

A large European population study by Weidinger et al.⁸⁸ Weidinger et al.
Analysis of SPINK5, KLK7, and FLG polymorphisms and eczema risk. J Allergy Clin Immunol, 2008 (2,774 cases, 10,607 controls) found a maternal transmission effect for rs2303067 but concluded it is not a major population-level eczema risk factor in unselected cohorts. This contrast with the Dežman study likely reflects phenotypic heterogeneity: the SPINK5 variant's effect is most pronounced in early-onset, barrier-driven atopic dermatitis — not in the broader, genetically heterogeneous eczema population. Studies of asthma alone have found no association, consistent with SPINK5's predominantly cutaneous and mucosal expression.

The Japanese population provided some of the earliest evidence. Kato et al.⁹⁹ Kato et al.
SPINK5 gene polymorphisms and atopic dermatitis in Japanese. Br J Dermatol, 2003 and Nishio et al.¹⁰¹⁰ Nishio et al.
SPINK5 polymorphisms and atopic dermatitis in Japanese. Genes Immun, 2003 both reported significant SPINK5–AD associations using transmission disequilibrium tests, establishing cross-ethnic consistency.

Practical Actions

The Lys420 allele's primary consequence is structural: impaired LEKTI activity leads to chronic subclinical protease hyperactivity in the skin, producing a leakier barrier and a lower threshold for atopic sensitisation. The actionable implications fall into three domains:

Barrier protection: Physical barrier support — particularly emollients that reduce transepidermal water loss — is specifically indicated by the mechanism, not as general skincare advice. Emollient therapy has clinical trial support for reducing AD incidence and severity, and the rationale is even stronger when LEKTI activity is constitutively reduced.

Trigger avoidance: A compromised LEKTI-mediated barrier admits allergens, irritants, and microbes more readily. This makes trigger identification — through specific IgE testing or patch testing — more productive than in barrier-intact individuals.

Monitoring for severe presentations: Homozygous Lys420 individuals (AA genotype) who also carry any second SPINK5 loss-of-function allele (rare, but present in the population) risk a Netherton-like phenotype. Severe early-onset ichthyosis, recurrent skin infections, and marked atopy in combination warrant SPINK5 gene sequencing.

Interactions

SPINK5 × FLG (filaggrin) variants: Weidinger et al. found no statistical interaction between rs2303067 and FLG loss-of-function variants (R501X, 2282del4) in their large European cohort, suggesting the two mechanisms — LEKTI impairment (protease pathway) and filaggrin loss (structural scaffold pathway) — act in parallel rather than synergistically. Carrying risk variants at both loci likely increases absolute AD risk additively. Related SPINK5 variants (rs2303065, rs2280099, rs8111930) have been examined in haplotype analyses; the Lys420Glu variant is generally the most functionally characterized within the SPINK5 locus.

SPINK5 × KLK5/KLK7 variants: Weidinger et al. also tested KLK7 (rs11567785) alongside SPINK5; neither showed interaction. The SPINK5/kallikrein axis is a candidate for compound effects, but published interaction data remain sparse.

The human cochlea relies on an extraordinary feat of ion management: within the spiral organ of Corti, potassium ions¹¹ potassium ions
K+; the primary charge carrier in cochlear mechanosensory transduction flow through hair cells during sound detection and must be continuously recycled through a network of gap junction channels before they can cause cellular toxicity. Connexin 26, encoded by GJB2²² Connexin 26, encoded by GJB2
Gap Junction Protein Beta-2; the most common cause of hereditary non-syndromic hearing loss worldwide is the principal protein of these recycling channels in the cochlear supporting cell network. The M34T variant (c.101T>C, p.Met34Thr, rs35887622) is a missense substitution in the first transmembrane domain of connexin 26 that substantially reduces channel conductance without eliminating it — creating a partial-loss-of-function allele that behaves quite differently from the severe truncating mutations that dominate the GJB2 literature.

Unlike c.35delG (rs80338939), which eliminates connexin 26 protein and causes severe-to-profound congenital deafness, M34T retains some channel activity. This subtlety has significant clinical consequences: homozygous M34T individuals typically have mild hearing loss (median pure-tone average ~30 dB), hearing loss may not be present at birth or may pass newborn screening, and onset often occurs in childhood or early adulthood. The result is a condition that is biologically meaningful but clinically easy to miss — and historically controversial because its high population frequency (approximately 1.5% carrier rate in Europeans) initially suggested it might be benign.

The Mechanism

M34T substitutes the nonpolar methionine at position 34 with the hydroxyl-bearing threonine, located within the first transmembrane helix (TM1) of connexin 26. This position is structurally critical: methionine 34 forms a hydrophobic contact with tryptophan 3³³ hydrophobic contact with tryptophan 3
W3; located in the N-terminal helix that lines the channel pore of the adjacent subunit. Molecular dynamics simulations show that the M34T substitution disrupts this hydrophobic interaction, altering the geometry of the pore funnel and causing the channel to reside primarily in a low-conductance state (approximately 13 picosiemens, versus ~120 pS for wild-type connexin 26 channels) — a roughly 90% reduction in single-channel conductance.

Importantly, M34T channels retain some residual activity rather than being completely non- functional. This distinguishes M34T from frameshift mutations and explains both the milder audiological phenotype and the reduced penetrance compared with loss-of-function alleles. Coexpression of wild-type and M34T connexin 26 in heterologous systems has also demonstrated a dominant-negative effect⁴⁴ dominant-negative effect
The mutant subunit incorporates into hexameric connexons alongside wild-type subunits, reducing the conductance of the entire channel complex, which may explain rare reports of apparent dominant inheritance in families. However, the weight of clinical and population evidence supports autosomal recessive inheritance as the operational mode in most cases.

The Evidence

The definitive classification of M34T as pathogenic came from the ClinGen Hearing Loss Variant Curation Expert Panel in 2019⁵⁵ ClinGen Hearing Loss Variant Curation Expert Panel in 2019
Shen et al., Genetics in Medicine; PMID 31160754, which reviewed functional, allelic, segregation, and population data for both M34T and the related V37I variant (rs72474224). The panel concluded that both variants are pathogenic for autosomal recessive nonsyndromic hearing loss with variable expressivity and incomplete penetrance. Despite the relatively high allele frequency in European populations (~1.5%), the evidence that M34T is significantly overrepresented in hearing loss cohorts compared to population controls outweighed the frequency concern.

Quantitative phenotyping data comes from a multicenter study of 1,531 biallelic GJB2 cases across 16 countries⁶⁶ multicenter study of 1,531 biallelic GJB2 cases across 16 countries
Snoeckx et al., PMID 16303844. M34T/M34T homozygotes had a median pure-tone average of 30 dB (mild hearing loss), while 35delG/M34T compound heterozygotes had a median of 34 dB. Both were among the three mildest genotype classes observed — far milder than the 35delG/35delG homozygotes, who had a median approaching severe-profound loss. A Polish cohort study⁷⁷ Polish cohort study
Pollak et al. 2007, PMID 17935238 estimated M34T penetrance at approximately 1/10 relative to mutations of undisputed pathogenicity, and documented significantly later onset and a progressive rather than congenital course for M34T-associated hearing loss.

The partial and progressive nature of M34T-related hearing loss means it often escapes newborn hearing screening. Standard otoacoustic emission and auditory brainstem response testing in neonates may classify an infant with biallelic M34T as "normal hearing," with measurable loss appearing only in mid-childhood or even adulthood.

Practical Implications

Biallelic M34T individuals (GG genotype) should have audiological evaluation regardless of whether they passed newborn hearing screening, since the mild loss may be subclinical at birth. Annual audiograms allow early detection of progression before communication is affected. When hearing aid candidacy is reached (typically when thresholds in the speech frequencies average 25 dB or more), early fitting prevents the cognitive burden of straining to hear in noise. The audiogram shape is typically flat or mildly downsloping, a profile that responds very well to modern digital amplification.

Noise avoidance is particularly important: cochlear K+ recycling in biallelic M34T carriers has less reserve capacity, and animal and clinical data suggest that noise-induced hearing loss and ototoxic drug effects may be amplified in GJB2-related hearing impairment. Loud occupational or recreational noise (>85 dB time-weighted average) and ototoxic antibiotics such as aminoglycosides deserve special attention.

Single heterozygous carriers (AG genotype) have normal hearing. Their significance is reproductive: one in ~35 Europeans carries a GJB2 pathogenic variant, and partner carrier testing before pregnancy can identify couples at 25% risk per pregnancy of having a biallelic child with hearing loss.

Interactions

M34T produces compound heterozygous hearing loss when inherited alongside other pathogenic GJB2 alleles on the opposite chromosome. The most common combination in European populations is M34T/35delG (rs80338939): compound heterozygotes have a median threshold around 34 dB, milder than 35delG homozygotes but generally worse than M34T homozygotes. Compound M34T heterozygosity with the Asian-dominant c.235delC allele or the Ashkenazi 167delT (rs80338942) also produces mild-to-moderate hearing loss. The clinical rule in DFNB1-spectrum hearing loss is that severity correlates with the less severe of the two alleles — since M34T is a partial loss-of-function allele, it "protects" compound heterozygotes from the severe phenotype associated with the co-inherited truncating allele.

Large deletions in the neighbouring GJB6 gene⁸⁸ neighbouring GJB6 gene
Encodes connexin 30, which forms heteromeric gap junctions with connexin 26 in cochlear supporting cells — particularly del(GJB6-D13S1830) — can also serve as a second allele in trans with M34T. A single GJB2 M34T allele in a deaf individual with no apparent second GJB2 variant should prompt testing for GJB6 regulatory deletions.

SLC19A1 (Solute Carrier Family 19 Member 1), also known as the reduced folate carrier (RFC1), is the primary transporter that moves folate and antifolate drugs from the bloodstream into cells. The well-characterized G80A variant rs1051266¹¹ rs1051266
The missense SLC19A1 variant most extensively studied for folate transport and methotrexate pharmacogenomics sits in the transmembrane domain and directly affects transporter function. rs3788205 is a separate intronic variant in the same gene — it does not alter the protein itself, but it tags broader genetic variation across the SLC19A1 locus through linkage with adjacent functional variants.

The Mechanism

As an intronic variant, rs3788205 does not directly change the SLC19A1 amino acid sequence. Intronic variants can theoretically influence gene expression through effects on splicing enhancers, regulatory elements, or transcription factor binding sites embedded within introns. However, no functional characterization of this specific site has been published to date. The variant's appearance across multiple folate-pathway disease studies most likely reflects linkage disequilibrium ²² Linkage disequilibrium (LD): nearby variants on the same chromosome are inherited together, so one can be a statistical proxy for another without directly causing any effect with rs1051266 or other functional SLC19A1 variants. The T allele is the minor allele globally (~28% overall, ~30% in Europeans, only ~7% in Africans per dbSNP ALFA data), making it an informative population marker for SLC19A1 haplotype structure.

The Evidence

The clearest direct finding comes from a Phase III lung cancer trial³³ Phase III lung cancer trial
Smit EF et al. Biomarker analysis of pemetrexed-carboplatin vs. etoposide-carboplatin in SCLC. Annals of Oncology, 2012, which found that rs3788205 interacted with gamma-glutamyl hydrolase (GGH)-associated SNPs to predict overall survival in patients receiving pemetrexed-carboplatin. This is biologically plausible since pemetrexed, like methotrexate, depends on RFC1/SLC19A1 for cellular entry. An Italian case-control study⁴⁴ Italian case-control study
Girardi A et al. RFC1 and non-syndromic cleft lip/palate association study in Italy. J Craniomaxillofac Surg, 2014 examined rs3788205 alongside rs1051266 and rs4818789 in the context of cleft lip with or without cleft palate, reporting weak association signals across the three RFC1 polymorphisms. A Japanese autism spectrum disorder study⁵⁵ Japanese autism spectrum disorder study
Mahmuda NA et al. SLC19A1/RFC1 SNPs in autism spectrum disorder. Int J Mol Sci, 2016 included rs3788205 in a 13-SNP SLC19A1 panel but found no significant association after correction for multiple testing. rs3788205 is not among the five SLC19A1 tagSNPs that reached corrected significance in the colorectal adenoma study Levine AJ et al., 2011⁶⁶ Levine AJ et al., 2011
Cancer Causes Control, folate pathway variation and distal colorectal adenoma.

Taken together, the evidence for this variant as an independent risk factor is weak. The evidence level is emerging — the variant appears across folate-pathway studies but has not been replicated with a clear, directional effect in any single phenotype.

Practical Context

If you carry the minor T allele — particularly as a TT homozygote — your result reflects a less common SLC19A1 haplotype that co-occurs with other folate pathway variants in studies examining anti-folate drug response, birth defects, and gastrointestinal cancer risk. The practical implications are best understood in the context of your other folate pathway results, especially rs1051266 (the G80A missense variant in the same gene) and MTHFR variants.

The most actionable approach for anyone with T-allele status at this locus is to ensure optimal folate intake and to use methylfolate rather than synthetic folic acid — advice consistent with the broader SLC19A1 pathway evidence.

Interactions

rs3788205 is in the same gene as rs1051266 (G80A, His27Arg), the primary functional variant in SLC19A1. Compound haplotypes across these two sites define distinct SLC19A1 genetic backgrounds. Studies of methotrexate toxicity use haplotype-based approaches encompassing both variants alongside rs7499 and rs2838956. If you carry the G80A T allele at rs1051266 in addition to the minor T allele here, you may be on a specific SLC19A1 haplotype associated with altered folate transporter behavior.

CYP2D6 is one of the most clinically significant drug-metabolizing enzymes in the human body. Despite making up only about 2% of liver CYP450 content, it metabolizes approximately 25% of all clinically used medications. The *4 allele¹¹ rs3892097 is the most common non-functional variant in European populations, carried by about 25% of people.

The Mechanism

The CYP2D6*4 variant is a splice site mutation²² A splice site mutation disrupts the boundary between coding and non-coding DNA, preventing correct protein assembly³³ C>T on the plus strand (historically called G1846A on the coding strand) at the intron 3/exon 4 boundary that causes aberrant mRNA splicing, producing a completely non-functional enzyme. Unlike variants that merely reduce activity, *4 abolishes CYP2D6 function entirely from that allele. Individuals homozygous for *4 (TT) are classified as CYP2D6 poor metabolizers.

Prodrugs vs. Active Drugs

The clinical impact of CYP2D6 status depends on whether a medication is a prodrug⁴⁴ A prodrug is inactive until the body converts it to its active form or an active drug (needs CYP2D6 to be eliminated).

For prodrugs like codeine and tramadol, poor metabolizers get NO pain relief because these drugs cannot be converted to their active forms⁵⁵ Codeine is converted to morphine; tramadol to O-desmethyltramadol. This is not a matter of dose adjustment - these drugs simply will not work.

For active drugs like many antidepressants⁶⁶ e.g. fluoxetine, paroxetine, venlafaxine, beta-blockers, and tamoxifen, poor metabolizers accumulate higher drug levels, increasing the risk of side effects and toxicity.

The Evidence

CYP2D6 pharmacogenomics has the strongest evidence base of any pharmacogene. The Clinical Pharmacogenetics Implementation Consortium (CPIC)⁷⁷ Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG)⁸⁸ Dutch Pharmacogenetics Working Group (DPWG)
Dutch Pharmacogenetics Working Group at PharmGKB have published dosing guidelines for over 30 CYP2D6 substrate medications. Major medical centers now routinely test CYP2D6 before prescribing certain medications. The Gaedigk activity score system⁹⁹ Gaedigk activity score system
Gaedigk A et al. The CYP2D6 activity score. Clin Pharmacol Ther, 2008 translates complex CYP2D6 genotypes into a quantitative measure of predicted enzyme activity, enabling standardized phenotype assignment.

What You Should Do

If you carry even one *4 allele, this is clinically actionable information. Share your CYP2D6 status with all prescribing physicians and pharmacists. Consider requesting your full CYP2D6 genotype through clinical pharmacogenomic testing, as 23andMe only captures some of the known variants.

Most people know that DNA variants in protein-coding regions can alter how enzymes and channels work. But rs5210 tells a more subtle story. This variant sits in the 3' untranslated region (3' UTR) of KCNJ11 — the gene encoding Kir6.2, the pore-forming subunit of the ATP-sensitive potassium (KATP) channel¹¹ ATP-sensitive potassium (KATP) channel
The KATP channel in pancreatic beta cells links glucose metabolism to insulin secretion. When glucose rises, ATP builds up, closes the channel, depolarizes the cell, and triggers insulin release. Unlike the neighboring rs5219 (E23K) missense variant, rs5210 doesn't change the Kir6.2 protein sequence at all — instead, it appears to influence how much of the protein gets made.

rs5210 is co-listed with rs5219 as a KCNJ11 co-variant, and the two SNPs are in moderate linkage disequilibrium in most populations. However, rs5210 has independent associations with both type 2 diabetes risk and sulfonylurea drug response, making it worth profiling on its own merits.

The Mechanism

The rs5210 variant lies within a conserved region of the KCNJ11 3' UTR. A meta-analysis²² A meta-analysis
Qin LJ et al. Meta-analysis of association of common variants in the KCNJ11-ABCC8 region with type 2 diabetes. Genet Mol Res, 2013 proposed that the risk allele (G) maintains a binding site for the microRNA hsa-miR-1910, while the A allele disrupts this binding site. MicroRNAs binding to the 3' UTR typically suppress gene expression by destabilizing mRNA or blocking translation³³ destabilizing mRNA or blocking translation
miRNA-3'UTR interactions are a major post-transcriptional regulatory mechanism controlling protein abundance. If the G allele retains miR-1910 binding, this could reduce KCNJ11 expression and lower Kir6.2 protein levels, leading to reduced KATP channel density in beta-cell membranes. Fewer functional channels could subtly impair the glucose-sensing mechanism.

This mechanism remains proposed rather than fully validated — the functional studies needed to confirm miR-1910 regulation of KCNJ11 in human beta cells have not yet been published. The 3' UTR location and the observed T2D association are consistent with the model, but the molecular details are still emerging.

The Evidence

The key meta-analysis⁴⁴ meta-analysis
Qin LJ et al. Genet Mol Res, 2013 analyzed 41 case-control studies encompassing 61,879 subjects across multiple populations. The rs5210 G allele showed an allelic odds ratio of 1.16 (95% CI: 1.08–1.24; P = 0.023) for type 2 diabetes — a modest but statistically robust association. For context, this effect size is comparable to the well-established rs5219 E23K variant (~OR 1.12 per allele), which has been studied far more extensively.

Beyond diabetes risk, rs5210 appears to affect drug response. In a study of T2D patients, rs5210 was associated with improved clinical efficacy of gliclazide⁵⁵ rs5210 was associated with improved clinical efficacy of gliclazide
Wang Y et al. Correlation between KCNJ11 gene polymorphisms, type 2 and post-transplant diabetes mellitus in Asian Indian population. Genes Dis, 2015, a sulfonylurea that works by binding to the SUR1 subunit and closing the KATP channel. A separate cohort study found rs5210 associated with improved fasting plasma glucose response to treatment⁶⁶ rs5210 associated with improved fasting plasma glucose response to treatment
Gloyn AL et al., 2009.

An Indian population study found rs5210 associated with T2D under a dominant model (OR 2.07, 95% CI 1.30–3.27; P = 0.001), with larger effect sizes than seen in European populations — a pattern also observed for the related rs5219 variant. The variant showed positive association with gestational diabetes and OGTT values⁷⁷ positive association with gestational diabetes and OGTT values
Gaston J et al. Indian pregnant women study, 2018 in Indian women as well.

Not all studies agree: one Iranian study found no significant association in 111 T2D cases vs 82 controls (PMID 33853507), and a 2024 GDM meta-analysis covering 3 studies found no association with gestational diabetes (PMID 38932913). The overall evidence supports a real but modest effect, with possible population heterogeneity.

Practical Actions

The clinical takeaway from rs5210 runs parallel to, but is independent of, the better-known rs5219 variant. Carriers of the G allele (the majority of people) have a mildly elevated risk of type 2 diabetes, expressed additively — two G alleles confer modestly more risk than one. The A allele is the protective minority genotype.

For sulfonylurea-treated diabetes, rs5210 G allele carriers may show better response to gliclazide specifically, and possibly to the sulfonylurea class broadly — this variant is one element of the pharmacogenomic picture your doctor can consider when calibrating doses.

Magnesium and chromium support insulin production and signaling — they are particularly relevant when beta-cell KATP channel function is subtly impaired.

Interactions

rs5210 sits approximately 1,300 bp upstream of rs5219 (E23K) in the KCNJ11 gene. The two variants are in partial linkage disequilibrium and may act in combination on KATP channel function — rs5219 at the protein level, rs5210 at the expression level. Studies examining the KCNJ11-ABCC8 region as a haplotype block consistently find both variants independently contribute to T2D and sulfonylurea pharmacogenomics.

The ABCC8 rs757110 (Ser1369Ala) variant encodes the SUR1 subunit — the other half of the KATP channel complex. ABCC8 and KCNJ11 variants together form the complete pharmacogenomic picture for sulfonylurea response. Carrying risk alleles at rs5210, rs5219, and rs757110 simultaneously is expected to compound the effect on insulin secretion, though dedicated multi-variant analysis of this specific combination is limited.

About 121 kilobases upstream of the PER2 gene¹¹ PER2 gene
Period Circadian Regulator 2: one of the core negative-feedback proteins in the mammalian circadian clock. PER2 protein accumulates during the day, enters the cell nucleus to inhibit its own transcription, then gets degraded — resetting the clock for the next 24-hour cycle sits a regulatory region that acts as a long-range tuner of PER2 expression. The rs55694368 variant in this region was first identified in a 2016 genome-wide association study of nearly 90,000 people and independently confirmed in a 2019 meta-analysis of 697,828 individuals — one of the largest chronotype studies ever conducted. Carriers of the T allele (about 13% of people of European ancestry) show a measurable shift in their biological clock toward eveningness.

The Mechanism

PER2 expression is tightly controlled not just by its promoter but by distal enhancer elements²² enhancer elements
Stretches of DNA, often tens to hundreds of kilobases from a gene, that bind transcription factors and loop back to the promoter to boost or tune gene expression. They are especially important for genes like PER2 that must be precisely timed that bind CLOCK/BMAL1³³ CLOCK/BMAL1
The master activator complex of the mammalian circadian clock. CLOCK and BMAL1 proteins form a dimer that drives transcription of PER2 and other clock genes; PER2 protein in turn accumulates and inhibits CLOCK/BMAL1 — completing the core feedback loop and other transcription factors. rs55694368 sits in one such upstream regulatory region. The T allele is thought to reduce the efficiency of this enhancer, producing slightly less PER2 protein per cell cycle. Because PER2 is a transcriptional repressor that drives its own oscillation, reduced levels slow the feedback loop slightly, delaying the phase of the clock — shifting the entire sleep-wake cycle toward later timing. This is a distinct regulatory haplotype from the PER2 5'UTR variant (rs2304672) and the coding variant rs35333999, meaning rs55694368 tags an independent route to the same outcome.

The Evidence

The initial discovery came from Hu et al.⁴⁴ Hu et al.
Hu Y et al. GWAS of 89,283 individuals identifies genetic variants associated with self-reporting of being a morning person. Nat Commun, 2016, a genome-wide association study of 89,283 individuals from the 23andMe cohort. The study identified seven loci near established circadian genes, including rs55694368 at PER2, reaching genome-wide significance (P=2.6×10⁻⁹). The G allele carried OR≈1.16 for self-reported morningness, meaning T carriers have approximately 14% lower odds of being a morning person per copy of T (OR≈0.86 for morningness per T allele copy).

Replication and extension came from the landmark Jones et al. chronotype GWAS⁵⁵ Jones et al. chronotype GWAS
Jones SE et al. Genome-wide association analyses of chronotype in 697,828 individuals provides insights into circadian rhythms. Nat Commun, 2019, which expanded the known genetic architecture of chronotype from 24 to 351 loci in a meta-analysis of UK Biobank and 23andMe data. The PER2 region was confirmed among the circadian-gene-enriched set. Mendelian randomization in that study found that genetically predicted later chronotype causally associates with poorer mental health outcomes, independent of sleep duration — adding clinical weight to this locus beyond its effect on sleep timing alone.

The effect size at rs55694368 is modest in isolation — as expected for a common regulatory variant influencing a complex trait — but it tags a distinct regulatory haplotype from the other two PER2 variants in the GeneOps database (rs2304672 and rs35333999), providing independent information about your circadian regulation.

Practical Implications

Chronotype is substantially genetic, and the T allele at rs55694368 is one piece of that genetic architecture. Carriers of one or two T alleles have a slightly stronger biological tendency toward later sleep timing. For most people in standard day-shift jobs, this manifests as needing slightly more effort to maintain early schedules. For T allele carriers in shift work⁶⁶ shift work
Work schedules that rotate across evenings, nights, and weekends, forcing the body clock to repeatedly misalign with work and social timing. Epidemiological studies link shift work to elevated rates of metabolic syndrome, cardiovascular disease, depression, and cancer or trans-meridian travel, the mismatch between biology and schedule can be more pronounced. The practical tools for managing chronotype — strategic light exposure, light-avoidance at night, and consistent anchoring of the sleep-wake cycle — are particularly valuable when the genetic tendency runs counter to social demands.

Interactions

rs55694368 tags a regulatory haplotype that is independent of, and potentially additive with, the PER2 5'UTR variant rs2304672 (associated with morning preference, opposite direction to rs55694368-T) and the coding variant rs35333999 (V903I, also eveningness-associated). A carrier of both rs55694368-TT and rs35333999-TT would carry two independent genetic pushes toward eveningness within the same gene. The CLOCK activator rs1801260 sits on the opposite side of the feedback loop: the G allele (eveningness-associated) and rs55694368-T may compound toward later sleep timing through distinct mechanisms — rs1801260 reducing CLOCK transcriptional activity and rs55694368 reducing PER2 enhancer response. Combined effects across these PER2 and CLOCK loci have not been formally tested but represent a plausible interaction for carriers of multiple evening-preference alleles.

The shape of your body — whether fat accumulates at the waist or at the hips — is not purely a matter of diet and exercise. A robust body of genetic research has identified RSPO3 (R-spondin 3) as the single strongest genetic determinant of waist-to-hip ratio adjusted for BMI¹¹ waist-to-hip ratio adjusted for BMI
WHRadjBMI — a measure of fat distribution that is independent of total body fatness; it captures whether fat concentrates in the abdomen (android) or hips and thighs (gynoid), a trait that independently predicts cardiometabolic disease beyond obesity itself. The rs9491696 variant within RSPO3 is one of two independent GWAS signals at this locus and is in high linkage disequilibrium (r² = 0.89) with the sentinel proxy variant rs1936807. Together, these signals explain a meaningful portion of the variance in human body shape, with effects that are substantially stronger in women than in men.

The Mechanism

RSPO3 encodes a secreted R-spondin protein²² R-spondin protein
R-spondins (RSPO1-4) are a family of secreted glycoproteins that potentiate WNT signaling by binding LGR4/5/6 receptors, blocking the ubiquitin ligases RNF43 and ZNRF3, and thereby keeping Frizzled WNT receptors at the cell surface. WNT/beta-catenin signaling is a potent suppressor of adipogenesis: when WNT signaling is active, preadipocytes are directed away from fat-cell fate. RSPO3 amplifies this WNT brake in a depot-specific fashion.

The rs9491696 G allele lies within intron 1 of RSPO3 and falls in an adipocyte enhancer region. Mechanistic studies using allele-specific expression analyses and formal co-localisation with adipose cis-eQTLs confirmed that the G allele increases RSPO3 expression specifically in mature adipocytes and in abdominal subcutaneous adipose tissue. The downstream effects are strikingly depot-specific. In gluteal (hip/thigh) progenitors³³ gluteal (hip/thigh) progenitors
Gluteofemoral fat — the fat depot at hips, buttocks, and thighs — is considered metabolically protective, releasing anti-inflammatory adipokines and sequestering atherogenic lipids away from visceral organs, higher RSPO3 suppresses adipogenesis and increases susceptibility to apoptosis — meaning fewer, larger gluteal fat cells are formed and they die more readily. In abdominal progenitors, the same RSPO3 signal stimulates proliferation. The net effect: fat shifts from the lower body to the abdomen, increasing the waist-to-hip ratio. This explains why G allele carriers tend toward an apple shape rather than a pear shape, independent of how much total fat they carry.

Estrogen appears to suppress RSPO3 expression in females, which may partly explain why women generally carry more lower-body fat than men. When estrogen levels fall after menopause, RSPO3 expression rises, contributing to the central fat redistribution that accompanies the menopausal transition — a shift that carries increased cardiovascular risk.

The Evidence

The RSPO3 locus was first identified by Heid et al. 2010⁴⁴ Heid et al. 2010
Meta-analysis of 32 GWAS with up to 77,167 participants plus follow-up in up to 113,636 individuals; the RSPO3 locus was the strongest signal genome-wide for WHRadjBMI as the strongest genetic determinant of WHRadjBMI. Seven of the 13 loci identified showed marked sexual dimorphism, all with stronger effects in women. This was replicated in the larger Shungin et al. 2015⁵⁵ Shungin et al. 2015
Meta-analysis in 224,459 individuals of European and other ancestries; identified 49 novel WHRadjBMI loci on top of the 2010 findings meta-analysis (224,459 individuals), and in the most powerful analysis to date, Pulit et al. 2019⁶⁶ Pulit et al. 2019
694,649 individuals; identified 463 independent signals in 346 loci, the largest genetic atlas of body fat distribution published (694,649 participants), which confirmed RSPO3 among the most significant hits.

The mechanistic connection was established by Loh et al. 2020⁷⁷ Loh et al. 2020
Mechanistic study combining GWAS, adipose eQTL co-localisation, allele-specific expression, in vitro knockout in human adipose progenitors from multiple depots, and zebrafish rspo3 mutant models; published in Nature Communications: rs9491696 and the primary signal rs72959041 both increase RSPO3 expression in subcutaneous adipocytes. The WHRadjBMI-increasing G allele was associated with reduced leg fat mass and an increase in android fat. In vitro, RSPO3 knockdown in gluteal progenitors enhanced adipogenesis, while RSPO3 knockdown in abdominal progenitors suppressed proliferation — confirming opposite depot roles. The android/gynoid fat ratio showed a significant association (beta = 0.03, p = 0.0008) in Oxford Biobank analyses. Zebrafish rspo3 mutants displayed altered fat distribution patterns consistent with the human data.

Relevance to lipedema: a GWAS of an inferred lipedema phenotype⁸⁸ GWAS of an inferred lipedema phenotype
24,450 cases and 165,227 controls from the UK Biobank, defined by high leg fat percentage with small waist; 18 genome-wide significant loci identified in the UK Biobank identified the RSPO3 locus (rs72959041, OR = 1.24, p = 2.7×10⁻¹⁹) among 18 loci associated with the lipedema phenotype. This directly links RSPO3's role in promoting lower-body fat loss to the pathological absence of that fat redistribution seen in lipedema, where gynoid fat is locked in place and resistant to mobilization. The RSPO3 locus was among several WHRadjBMI loci known to exert stronger effects in women.

Additionally, the RSPO3 locus demonstrates pleiotropy⁹⁹ pleiotropy
Pleiotropy occurs when a single genetic variant affects multiple biological traits; RSPO3 variants affect both adipose and skeletal tissues through the shared WNT pathway across adipose and skeletal tissues: RSPO3 variants also associate with trabecular bone mineral density and fracture risk, with the fracture-reducing allele associated with increased RSPO3 expression and greater trabecular bone density. This has implications for G allele carriers: the same variant that shifts fat toward the abdomen may confer modest skeletal benefits.

Practical Actions

For G allele carriers — particularly women — the actionable implications focus on three areas: monitoring cardiometabolic risk markers that android fat distribution worsens, counteracting abdominal fat accumulation through dietary approaches that target visceral/subcutaneous abdominal fat specifically, and understanding that body-shape changes with menopause (or other estrogen-depleted states) are partly genetically driven and predictable.

DEXA body composition scans, which measure the android/gynoid fat ratio directly, provide genotype-relevant feedback: G allele carriers with a high android/gynoid ratio are expressing their genotype and face higher cardiometabolic risk than overall BMI alone suggests. Fasting insulin and triglyceride/HDL ratio are the most genotype-relevant biomarkers to monitor, as the RSPO3 variants are specifically associated with insulin-resistant phenotypes in GWAS studies.

For CC homozygotes (no G allele), fat distribution tends toward the gynoid (pear) pattern. In the context of lipedema research, the CC genotype represents the direction in which RSPO3 activity is lower — allowing more lower-body fat accumulation. This is consistent with the lipedema phenotype, though lipedema involves multiple genetic and biological factors beyond this single locus.

Interactions

rs9491696 is one of two independent GWAS signals at the RSPO3 locus; the other is rs72959041 (the primary/sentinel signal). These two SNPs are not in complete LD with each other (they represent independent signals adjustable for each other), so carriers of both risk alleles may have additive effects on WHRadjBMI. The mechanistic study confirmed both signals act through increased RSPO3 expression in adipocytes.

The RSPO3 locus also shares the WNT pathway with other fat distribution and lipedema-related loci identified in GWAS. GRB14-COBLL1¹⁰¹⁰ GRB14-COBLL1
A locus associated with WHRadjBMI and replicated in the clinical lipedema GWAS; GRB14 modulates insulin receptor signaling in adipose tissue and VEGFA¹¹¹¹ VEGFA
Vascular endothelial growth factor A; associated with fat distribution and replicated in clinical lipedema GWAS; may influence adipose vascularization and lymphatic function loci identified in the lipedema phenotype GWAS may compound RSPO3 effects, as these pathways collectively regulate adipose progenitor differentiation, vascular support, and insulin sensitivity.

Supervisor note — candidate compound action: individuals carrying the risk (G) allele at rs9491696 and the risk allele at rs72959041 (the sentinel RSPO3 signal) represent the highest-RSPO3-expression genotype at this locus. These two signals are conditionally independent and additive; combined carriers may have the greatest shift toward android fat distribution and the highest associated insulin resistance risk at this locus. A compound recommendation targeting insulin sensitivity monitoring (fasting insulin, HOMA-IR, triglyceride/HDL ratio) along with abdominal fat tracking via DEXA would be appropriate for this combination.

The conversion of dietary plant omega-3s into DHA — the brain's dominant structural fat — is governed by a chain of enzymes whose efficiency varies widely between individuals. ELOVL2 (elongase of very long chain fatty acids protein 2) catalyzes the critical elongation step that converts EPA (20:5) into DPA (22:5) and then toward DHA (22:6). The rs953413 variant, sitting in the first intron of ELOVL2, controls how much of this enzyme the liver makes. Unlike many GWAS variants whose functional mechanism remains unknown, rs953413 has a precisely characterized molecular role: it sits inside a cooperative enhancer element¹¹ cooperative enhancer element
A regulatory DNA sequence that increases transcription of a nearby gene when transcription factors bind to it that is bound by the liver transcription factors FOXA1/FOXA2 and HNF4α²² FOXA1/FOXA2 and HNF4α
Hepatocyte nuclear factors — master regulators of liver gene expression that coordinate fatty acid, glucose, and bile acid metabolism.

The Mechanism

Pan and colleagues³³ Pan and colleagues
Pan G et al. rs953413 Regulates Polyunsaturated Fatty Acid Metabolism by Modulating ELOVL2 Expression. iScience, 2020 used luciferase reporter assays, ChIP-qPCR, and CRISPR/Cas9 editing in hepatic cell lines to show that the G allele of rs953413 preferentially recruits FOXA1, FOXA2, and HNF4α to an evolutionarily conserved intronic enhancer. This allele-specific transcription factor binding upregulates ELOVL2 expression. The A allele disrupts this binding, reducing ELOVL2 transcription. FOXA knockdown and direct Cas9 mutation of the enhancer both significantly downregulated ELOVL2 expression (p < 0.01), confirming the causal chain from SNP → transcription factor binding → ELOVL2 expression → LC-PUFA levels.

The downstream consequence is that A-allele carriers produce less ELOVL2 enzyme, slowing the EPA→DPA→DHA elongation cascade in the liver. This creates a phenotype with characteristically lower baseline DHA but paradoxically greater responsiveness to preformed omega-3 supplementation — a pattern seen across multiple independent intervention trials.

The Evidence

rs953413 was the lead variant in the original InCHIANTI GWAS⁴⁴ InCHIANTI GWAS
Tanaka T et al. Genome-wide association study of plasma polyunsaturated fatty acids in the InCHIANTI Study. PLoS Genet, 2009 of 1,075 Italian adults, where it reached p = 1.1×10⁻⁶ for plasma EPA — establishing ELOVL2 as a major genetic determinant of omega-3 fatty acid levels in humans. The signal replicated in 1,076 GOLDN study participants, where ELOVL2 variants were associated with DPA and DHA levels.

The most striking clinical data comes from an exploratory supplementation trial by Metherel and colleagues⁵⁵ Metherel and colleagues
Metherel AH et al. Higher Increase in Plasma DHA in Females Compared to Males Following EPA Supplementation May Be Influenced by a Polymorphism in ELOVL2: An Exploratory Study. Lipids, 2021. Young adults (n = 14–15 per group) received 3 g/day EPA for 12 weeks. Overall, females showed substantially greater plasma DHA increases than males (+23.8 vs. −13.8 nmol/mL; p < 0.01). When stratified by rs953413 genotype, the effect was dramatic: AA-genotype females gained +58.8 ± 11.5 nmol/mL DHA, compared to +4.34 ± 13.5 nmol/mL for GA+GG females and −29.1 ± 17.2 nmol/mL for AA males (p < 0.001). This sex × genotype interaction suggests that estrogen-mediated upregulation of the EPA→DHA elongation pathway partially compensates for the low-ELOVL2 A-allele phenotype in females, while AA-genotype males face the full deficit.

The Alsaleh 2014 fish oil trial⁶⁶ Alsaleh 2014 fish oil trial
Alsaleh A et al. ELOVL2 gene polymorphisms are associated with increases in plasma EPA and DHA proportions after fish oil supplement. Genes Nutr, 2014 of 367 subjects confirmed that ELOVL2 minor-allele carriers — across rs953413, rs2236212, and rs3734398 — showed approximately 30% higher plasma EPA and 9% higher DHA after 1.8 g/day fish oil supplementation (p = 0.002–0.017), reinforcing that preformed omega-3 supply strongly compensates for reduced endogenous elongation.

A notable additional dimension of this locus is its role in epigenetic aging⁷⁷ epigenetic aging
DNA methylation changes that accumulate with age and can be used to predict biological age independently of chronological age. Garagnani and colleagues⁸⁸ Garagnani and colleagues
Garagnani P et al. Methylation of ELOVL2 gene as a new epigenetic marker of age. Aging Cell, 2012 demonstrated that CpG island methylation in the ELOVL2 promoter/enhancer region correlates with chronological age at r = 0.92 across 501 subjects aged 9–99 years. The rs953413 variant sits within precisely this regulatory region. Whether the SNP's effect on transcription factor binding modulates the rate of age-associated methylation accumulation remains an open research question, but the overlap establishes this locus as a convergence point for fatty acid metabolism and biological aging biology.

Practical Implications

For AA-genotype individuals, the key implications are: (1) endogenous DHA synthesis from plant-derived ALA or EPA is constrained by reduced ELOVL2 activity; (2) preformed DHA supplementation bypasses this bottleneck and is well-supported by multiple intervention studies; (3) males with AA are at greater deficit than females because estrogen-mediated elongation partially compensates in women. Fish oil or algae-based DHA at 1–2 g/day is the most direct intervention, with the omega-3 index as the objective measure of adequacy.

Interactions

rs953413 is in partial linkage disequilibrium with rs2236212 in European populations, and both variants affect ELOVL2 activity through different mechanisms: rs2236212 is associated with reduced enzymatic elongation activity (Maguolo et al. 2021), while rs953413 acts upstream by controlling transcription factor binding and ELOVL2 gene expression. Carrying risk alleles at both loci may compound the reduction in DHA synthesis capacity. Upstream in the same pathway, FADS1/FADS2 variants (rs174547, rs174537) affect the desaturation of ALA to EPA — individuals with both FADS low-activity and ELOVL2 low-expression genotypes face impairment at two sequential steps, making plant-based omega-3 strategies essentially ineffective and preformed marine DHA the only reliable route to adequate status.

The 17q21 chromosomal region is the most replicated genetic risk locus for childhood asthma in the genome, with associations reported across dozens of studies in European, African, East Asian, and South Asian populations. For years, the gene driving this signal was assumed to be ORMDL3¹¹ ORMDL3
ORM1-like protein 3, a transmembrane ER protein that regulates ceramide synthesis and the unfolded protein response, whose expression is tightly regulated by 17q21 variants. But more recent functional work points to its neighbor, GSDMB (gasdermin B), as the causal effector — specifically, GSDMB's ability to trigger pyroptosis²² pyroptosis
A form of inflammatory programmed cell death in which cells release their contents into the surrounding tissue, driving local inflammation — distinct from apoptosis, which is non-inflammatory in airway epithelial cells.

rs2305480 sits within the GSDMB coding sequence on chromosome 17q21. On the plus (genomic) strand, the G allele is the reference, but it is also the risk allele: it encodes a proline at position 311 of the dominant GSDMB isoform, producing a protein with full pyroptotic capacity. The A allele, encoding serine at the same position (p.Pro311Ser), tags a haplotype carrying a protective splice variant (rs11078928) that removes exon 6 and abolishes GSDMB's ability to trigger inflammatory cell death. Most people carry at least one copy of the risk G allele — it is the population-major allele globally — making GG the most common genotype worldwide.

The Mechanism

GSDMB protein belongs to the gasdermin family, which evolved to perforate cell membranes under specific inflammatory conditions. When airway epithelial cells are exposed to viral or bacterial triggers, caspase-1³³ caspase-1
An inflammatory cysteine protease activated by the NLRP3 inflammasome in response to microbial danger signals cleaves GSDMB, releasing its N-terminal domain. This N-terminal fragment inserts into the cell membrane, forming pores that trigger pyroptotic cell death and release pro-inflammatory signals — interleukin-1β (IL-1β), IL-18, and HMGB1 — into the airway.

The splice variant tagged by the protective A allele at rs2305480 removes exon 6, which encodes 13 amino acids within the region essential for GSDMB's pore-forming activity. Without these residues, the protein loses pyroptotic capacity even when caspase-1 cleaves it. Panganiban et al.⁴⁴ Panganiban et al.
J Allergy Clin Immunol, 2018; multi-cohort study combining the GERA cohort and the EVE Consortium (diverse ancestry) showed that the G-allele haplotype (full pyroptotic GSDMB) confers risk while the A-allele haplotype (truncated, non-pyroptotic GSDMB) is protective: combined OR 0.85 (P=1.31×10⁻¹³) in the EVE Consortium.

Beyond pyroptosis, the Das et al. review⁵⁵ Das et al. review
Advances in Immunology, 2017; comprehensive review of 17q21 genes in asthma and immune diseases identified that GSDMB also modulates 5-lipoxygenase (5-LO) expression and TGF-β1 signaling — two further pathways that sustain airway inflammation and promote bronchial remodeling in asthma.

The Evidence

The GABRIEL Consortium GWAS⁶⁶ GABRIEL Consortium GWAS
Moffatt et al., NEJM 2010; 10,365 asthma cases and 16,110 controls from 23 European studies established rs2305480-G as a genome-wide significant risk allele for childhood-onset asthma (OR 1.18, 95% CI 1.11–1.23, P=6×10⁻²³), with an effect specific to childhood-onset disease — no comparable association appeared with adult-onset asthma. This age-specificity is consistent with GSDMB's role in shaping airway epithelial responses during the critical window of early respiratory development.

A Danish GWAS of severe asthma exacerbations⁷⁷ GWAS of severe asthma exacerbations
Bønnelykke et al., Nature Genetics 2014; 1,173 cases aged 2–6 years and 2,522 controls from national health registries identified the GSDMB locus among the strongest hits, with OR 1.32 (95% CI 1.23–1.39), consistent with a larger effect in younger children with more severe disease.

Critically, the signal extends across ancestries. Ober et al.⁸⁸ Ober et al.
Lancet Respiratory Medicine, 2020; expression QTL fine-mapping in African American children found that rs2305480 was the single most robust signal from the 17q21 locus in African Americans (OR 1.36, 95% CI 1.12–1.65, P=0.0014) — and was the most significant eQTL for GSDMB expression in upper airway epithelial cells in this population. This functional eQTL evidence directly links the genetic signal to altered gene expression in the relevant tissue.

A 2025 large-scale study across 13,000+ preschool children⁹⁹ 13,000+ preschool children
Fischer-Rasmussen et al., J Allergy Clin Immunol 2025; discovery in 15 cohorts, replication in 7 additional cohorts up to 5,000 children confirmed rs2305480 as a genome-wide significant determinant of early-onset wheeze (OR 1.26, 95% CI 1.17–1.33, P=2.30×10⁻¹⁶).

In UK asthmatic children, Tulah et al.¹⁰¹⁰ Tulah et al.
BMC Medical Genetics, 2013; 370 UK families with ≥2 asthmatic children showed that the Ser311Pro variant (rs2305480) associated not only with asthma diagnosis but with bronchial hyperresponsiveness and disease severity — indicating it modulates how reactive the airways are to triggers, not merely whether asthma is present.

Practical Actions

The practical implications of rs2305480 center on the early-childhood window when airway inflammatory programming occurs. For GG homozygotes, the key insight is that their airway epithelial cells produce full-activity GSDMB that releases inflammatory signals after respiratory infections — a process that is substantially amplified by environmental tobacco smoke exposure and respiratory viral infections in the first years of life. Actions focus on minimizing inflammatory triggers, optimizing lung function, and ensuring respiratory infections in childhood are treated promptly to limit airway inflammation.

For adults with GG genotype who already have asthma, the GSDMB mechanism suggests that biological triggers of NLRP3 inflammasome activation (respiratory infections, mold exposure, cockroach allergen) may be especially potent triggers compared to the population average.

Interactions

rs2305480 sits within the broader 17q21 asthma susceptibility block, which contains multiple variants in high linkage disequilibrium. The most important functional partners are:

rs11078928 — A splice-region variant that, when in combination with rs2305480-A on the same haplotype, directly removes exon 6 from GSDMB mRNA, eliminating pyroptotic activity. The combined A/A haplotype at these two positions produces the most protective profile.

rs8076131 — An ORMDL3 regulatory variant at the same locus that controls ER stress responses in airway epithelial cells independently of GSDMB. ORMDL3 and GSDMB effects may compound in the same airway cell population.

Gene-environment interaction: 17q21 risk genotype carriers show substantially higher associations between early-life respiratory infections and asthma onset compared to non-carriers, with ORs of 3.42–6.36 versus 1.84–2.44 in those without risk genotypes. Environmental tobacco smoke exposure in early life amplifies this interaction further.

The P2X7 receptor is an ATP-gated ion channel¹¹ ATP-gated ion channel
The receptor opens in response to high concentrations of extracellular ATP, typically released during tissue damage or cell death expressed primarily on immune cells, particularly microglia in the central nervous system. When activated by high concentrations of extracellular ATP—a danger signal released during tissue damage—P2X7 triggers a cascade of inflammatory responses. The Glu496Ala variant (rs3751143, also known as 1513A>C) is a well-characterized loss-of-function polymorphism²² well-characterized loss-of-function polymorphism
First described in 2001 by Gu et al., showing the variant leads to non-functional receptors that dramatically reduces receptor activity. This single amino acid change from glutamic acid to alanine at position 496 impairs both channel and pore function³³ impairs both channel and pore function
Studies show 70-90% reduction in ATP-induced responses in homozygous carriers, affecting inflammatory signaling and pain processing in ways that can be both protective and detrimental depending on the clinical context.

The Mechanism

The Glu496Ala substitution occurs in the C-terminal intracellular domain⁴⁴ C-terminal intracellular domain
This region is critical for receptor trafficking to the cell membrane and pore formation of the P2X7 receptor. This region is essential for proper receptor function, influencing both ATP binding affinity and the formation of the large membrane pore that allows passage of molecules up to 900 daltons. In homozygous CC individuals, the mutant receptors show severely reduced cell surface expression and near-complete loss of ATP-induced channel opening⁵⁵ near-complete loss of ATP-induced channel opening
Homozygous carriers show 9-fold lower ATP-induced ion efflux compared to wild-type. Heterozygous AC carriers express approximately half the functional receptor protein compared to AA wild-type individuals, resulting in intermediate phenotypes. The loss of function translates to impaired potassium efflux, reduced inflammasome activation⁶⁶ potassium efflux, reduced inflammasome activation
The NLRP3 inflammasome requires P2X7 activation for assembly and cytokine maturation, and delayed release of the pro-inflammatory cytokine IL-1β from immune cells in response to danger signals.

The Evidence

The clinical consequences of rs3751143 are context-dependent. In chronic pain conditions⁷⁷ chronic pain conditions
Study of diabetic neuropathic pain patients found loss-of-function carriers had lower pain scores, the C allele appears protective. A 2014 study of diabetic peripheral neuropathic pain found that while gain-of-function variants in P2RX7 were associated with higher pain intensity in females, the Glu496Ala loss-of-function variant showed the opposite pattern. This aligns with extensive animal research demonstrating that P2X7 knockout mice show reduced pain hypersensitivity⁸⁸ P2X7 knockout mice show reduced pain hypersensitivity
Disruption of P2X7 abolishes chronic inflammatory and neuropathic pain in mice in models of nerve injury and chronic inflammation. The receptor's role in activating spinal microglia—the immune cells that amplify pain signals in the central nervous system—explains this protective effect.

For cardiovascular disease⁹⁹ cardiovascular disease
Meta-analysis of ischemic heart disease and stroke in 14,000+ individuals, the loss-of-function variant also shows benefit. A 2012 study found the C allele significantly associated with reduced risk of ischemic stroke (OR 0.89, 95% CI 0.81-0.97, P=0.012) and decreased ischemic heart disease risk in smokers. The mechanism likely involves reduced inflammatory activation¹⁰¹⁰ reduced inflammatory activation
P2X7 drives inflammatory atherosclerosis through cytokine release from vascular immune cells in atherosclerotic plaques and vascular inflammation.

However, the dampened immune response creates vulnerabilities. In infectious disease¹¹¹¹ infectious disease
Study of 163 chronic Q fever patients over median 42-month follow-up, the CC genotype was associated with a 2.4-fold increased risk of treatment failure (SHR 2.42, 95% CI 1.16-5.05). The P2X7 receptor is crucial for immune cells to kill intracellular pathogens like Coxiella burnetii (the causative agent of Q fever), Mycobacterium tuberculosis¹²¹² Mycobacterium tuberculosis
Meta-analysis showing increased tuberculosis susceptibility with loss-of-function P2X7 variants, and Toxoplasma gondii. Loss-of-function impairs this pathogen clearance mechanism.

An interesting protective aspect emerges in acute inflammatory conditions¹³¹³ acute inflammatory conditions
Ex vivo study showing CC carriers had reduced cytotoxicity at high ATP concentrations. A 2012 study using whole blood models found that carriers of Glu496Ala were protected against the cytotoxic effects of high ATP levels during severe inflammation, while still maintaining some IL-1β release capacity—suggesting a potentially beneficial buffering effect during cytokine storms.

Practical Implications

For pain management, carriers of the C allele may experience naturally lower pain sensitivity, particularly in chronic inflammatory and neuropathic pain states¹⁴¹⁴ chronic inflammatory and neuropathic pain states
P2X7 expressed in spinal microglia drives central sensitization in chronic pain. This doesn't mean you're immune to pain, but the threshold for developing chronic pain after injury may be higher. If you do develop chronic pain, you might respond differently to treatments targeting inflammatory pathways.

The infectious disease implications are more concerning for CC homozygotes. While the absolute risk of problematic infections remains low¹⁵¹⁵ absolute risk of problematic infections remains low
Population studies show no major health burden despite ~3% CC frequency in most populations, awareness is important if you develop infections with intracellular bacteria (Q fever, tuberculosis, certain atypical infections). These may require more aggressive or prolonged antibiotic therapy. The cardiovascular protection is a modest but real benefit—the ~11% reduction in ischemic stroke risk translates to meaningful population-level protection.

The reduced inflammatory tone¹⁶¹⁶ reduced inflammatory tone
Carriers show lower baseline inflammatory cytokine production associated with this variant may also influence response to inflammatory triggers, vaccines, and immune-mediated conditions. Some evidence suggests carriers might have reduced vaccine-induced inflammatory responses, though protection is typically maintained through other immune pathways.

Interactions

Rs3751143 is one of several functionally significant variants in the highly polymorphic P2RX7 gene. Two gain-of-function variants, rs208294 (His155Tyr) and rs1718119 (Ala348Thr), have opposite effects—increasing P2X7 activity and pain sensitivity. Another variant, rs7958311 (Arg270His), has been more consistently associated with chronic pain conditions including fibromyalgia and irritable bowel syndrome, with a unique combined gain-of-function in channel opening but loss-of-function in pore formation. Individuals carrying both loss-of-function and gain-of-function P2RX7 variants may have complex phenotypes where effects partially cancel out. The net impact on pain sensitivity, inflammation, and immune function depends on which variants are present and their relative functional effects. Additionally, P2X7 function interacts with other purinergic receptors (P2X4, P2Y receptors) and inflammatory pathways (NLRP3 inflammasome, IL-1 signaling) that modulate its clinical effects.